China-based Innovent Biologics Inc. (HKG: 1801) announced that the first prescription has been filled in China for Pemazyre (pemigatinib), the world’s first targeted therapy for cholangiocarcinoma (bile duct cancer). The drug, an FGFR2-targeted protein kinase inhibitor, was originally discovered by US biotech Incyte Therapeutics and licensed to Innovent for Greater China in December 2018.
Drug Profile
Pemigatinib is approved to treat adult patients with advanced/metastatic or unresectable cholangiocarcinoma with FGFR2 gene fusions or rearrangements. It previously received market approvals in the US (April 2020), Taiwan (June 2021), and Hong Kong (January 2024). The China approval makes it the first selective FGFR receptor tyrosine kinase inhibitor in the country.-Fineline Info & Tech
